Streetbeat News

MAIA

MAIA Biotechnology, Inc.

https://www.MAIABiotech.com

Industry

Biotechnology

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Open

2.13

Mkt cap

54M

Volume

357K

High

2.29

P/E Ratio

-1.57

52-wk high

5.99

Low

1.80

Div yield

N/A

52-wk low

0.82

The article highlights significant intraday movements in health care stocks on Wednesday. Notable gainers include ENDRA Life Sciences (NDRA), Rezolute (RZLT), Bright Green (BGXX), Champions Oncology (CSBR), Kineta (KA), and CVRx (CVRX). On the losing side, SILO Pharma (SILO), Concord Medical Services (CCM), FibroBiologics (FBLG), Cue Health (HLTH), GH Research (GHRS), and MAIA Biotechnology (MAIA) experienced notable declines.

Portfolio Pulse from Benzinga Insights

June 05, 2024 | 4:31 pm

The article highlights the performance of various health care stocks during Tuesday's after-market session. Concord Medical Services (NYSE:CCM) saw a significant increase of 131%, while other stocks like Calidi Biotherapeutics (AMEX:CLDI) and Anitra (AMEX:AZTR) also experienced gains. On the losing side, BiomX (AMEX:PHGE) and SunLink Health Systems (AMEX:SSY) saw notable declines.

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 8:31 pm

MAIA Biotechnology shares are trading lower after the company reported new clinical data from its Phase 2 THIO-101 clinical trial. The trial evaluates THIO sequenced with the immune checkpoint inhibitor cemiplimab in patients with advanced non-small cell lung cancer who failed 2 or more standard-of-care therapy regimens.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 4:46 pm

MAIA Biotechnology announced that its clinical trial data for THIO shows efficacy in treating non-small cell lung cancer.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 12:42 pm

MAIA Biotechnology is set to present at the BIO International Convention 2024, which could provide significant exposure and potential partnerships for the company.

Portfolio Pulse from Benzinga Newsdesk

May 17, 2024 | 12:39 pm

MAIA Biotechnology, Inc. (NYSE:MAIA) announced that independent director Ms. Adelina Louie Ngar Yee purchased 19,665 shares and warrants for an equivalent number of shares. This transaction was part of a private placement of common stock and warrants to accredited investors and certain directors under the Company's 2021 Equity Incentive Plan. Ms. Louie, with a 30-year tenure at HSBC Group, has been a long-term supporter of MAIA, expressing confidence in the company's potential to deliver transformative cancer therapies.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 12:32 pm

MAIA Biotechnology shares surged following the announcement of a share purchase by director Stan Smith in a private placement.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 3:01 pm

MAIA Biotechnology announced a private placement in which Director Stan Smith, Ph.D., purchased 147,492 shares and an equal number of warrants. This move demonstrates insider confidence in the company's future prospects.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 12:12 pm

MAIA Biotechnology announced a private placement of 494,096 shares at a price of $2.034 per share, raising a total of $1 million. This move indicates the company's efforts to secure additional funding, possibly for research, development, or operational expansion.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 12:52 pm

MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company, announced that director Adelina Louie purchased 170,940 shares in a private placement. This purchase is part of a broader participation by five independent board members, highlighting confidence in MAIA's ongoing development of cancer treatments. The company appreciates the continued support from its top investors, including Adelina Louie and Stan Smith, as it progresses with its novel immunotherapies for cancer.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 7:03 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.